Document:

a2018630exhibit103

                                                                                                                                                                                                                                                                                                                                                                                                                                 Performance Award Agreement         This AGREEMENT between Knowles Corporation, a Delaware corporation (the “Company”), and [Employee   Name] (the “Grantee”) is made as of February 15, 2018 (the “Grant Date”), subject to the Grantee’s acceptance   of this Agreement in accordance with Section 14 hereof.        WHEREAS, the Company has adopted the Knowles Corporation 2018 Equity and Cash Incentive Plan (as  amended from time to time, the "Plan") in order to, among other things, motivate employees of the Company and  its subsidiaries to act in the long-term best interests of the Company and its stockholders; and     WHEREAS, the Company has determined to grant the Grantee a Performance Award in the form of   performance-based restricted stock units (“PSUs”) as provided herein to encourage the Grantee’s efforts toward   the continuing success of the Company.        NOW, THEREFORE, the Company and the Grantee agree as follows:      1. Grant of Performance Award.              1.1. The Company hereby grants to Grantee a award of PSUs with respect to its common stock, par value $0.01         per share, pursuant to the Plan, as indicated below, with a notional value based on the Company’s common         stock price on the Grant Date subject to adjustment pursuant to the terms provided in this Agreement         and Appendix A  (the “Award”) and the execution or electronic acceptance of this Agreement by the         Grantee.  Subject to Section 5, payment with respect to vested PSUs shall be made entirely in the form of         Common Stock in accordance with Section 3.                   Target number of PSUs: [Number]              1.2. This Agreement shall be construed in accordance and consistent with, and subject to, the provisions of the         Plan (the provisions of which are hereby incorporated by reference) and, except as otherwise expressly set         forth herein, the capitalized terms used in this Agreement shall have the same definition and meaning as set         forth in the Plan.             2. Performance Period.             The number of PSUs that the Grantee may earn is based on Knowles performance over a three year period (the       “Performance Period”). The Performance Period applicable to this Award shall commence and expire as      provided in Appendix A.          3. Determination of Award.             As soon as possible after the end of the Performance Period, the Compensation Committee of the Board of      Directors of the Company (the “Committee”) will certify whether the applicable performance objectives set forth      in Appendix A have been met for the Performance Period and determine the number of shares of Common      Stock, if any, payable in accordance with this Agreement, subject to the right of the Committee to adjust the     payout level of the PSUs as may be provided in the Plan or as the Committee otherwise determines to reflect the     impact of specified corporate transactions (such as a stock split or dividend), special charges, accounting or tax     law changes and other extraordinary or nonrecurring events.         4. Issuance of Common Stock.   

 

  Page 2            Following the end of the Performance Period, the Committee shall determine the final number of PSUs     earned by the Grantee, which determination shall be final and binding. As soon as practicable following the    date that the Committee certifies that the applicable performance measures have been met (but in any event no    later than March 15th after the end of the Performance Period), the Company shall issue a share of Common    Stock with respect to each vested PSU, less that number of shares of Common Stock which, subject to Section 9,    may be credited to cover applicable taxes on the Award, and such shares of Common Stock will be issued in the    form of book entry shares in the name of the Grantee. PSUs will only be settled in shares of Common Stock.    Any other settlement modality shall be considered an exception, which would have to be approved separately    by the Committee.    5. Forfeiture of Award.            5.1 Termination of Employment. If, prior to the end of the Performance Period, the Grantee’s employment     terminates for any reason, other than death, Disability, Retirement or Change in Control, this Award shall     automatically terminate and the Grantee shall not be entitled to receive any shares of Common Stock under    Sections 3 or 4 of this Agreement or otherwise under this Agreement.             5.1(a) Disability or Death. If the Grantee becomes Disabled or terminates employment due to death, the        Grantee shall vest in the number of PSUs that would have been earned, assuming achievement of the        performance measures at the “Target” level, and multiplied by a fraction equal to the months during the        Performance Period prior to the Grantee’s Disability or death over the months in the Performance Period.         The Award shall be settled within 60 days following the Grantee’s date of death or Disability.            5.1(b) Retirement.  If the Grantee’s employment terminates as a result of Retirement by the Grantee,        subject to the conditions set forth in Section 7, the Award shall continue to vest as if the Grantee’s        employment had not terminated until such time as the Performance Period has lapsed and the Award        shall be settled in accordance with Section 4.                   5.1(c) Change in Control.  If the Grantee’s employment terminates as a result of a Change in Control as        provided in Section 6.9(a) of the Plan, then the Award shall be settled within 60 days following the       Grantee’s termination of employment, based on the change in control vesting provisions set forth        in Appendix A; provided, however, if (i) the Award is considered “nonqualified deferred compensation”        within the meaning of Section 409A of the Code, (ii) the Grantee satisfies or would satisfy the age and        service requirements for “Retirement” during the Performance Period and (iii) the Change in Control is        not a “change in control event” within the meaning of Section 409A, then the Award shall be settled        following the conclusion of the Performance Period in accordance with Section 4 of this Agreement.  If a        Change in Control occurs as provided in Section 6.9(b) of the Plan where the Award is not effectively        assumed, then the Award shall be settled within 60 days following such Change in Control; provided,        however, the Award shall be settled at the times specified in Section 4 or, if earlier, Section 5.1(a) if        either (i) the Award is subject to Section 409A of the Code and the Change in Control does not constitute        a “change in control” event within the meaning of Section 409A of the Code or (ii) otherwise required to        comply with Section 409A of the Code.                  5.1(d) Definitions.                “Disability” or “Disabled” shall mean the permanent and total disability of the Grantee within        the meaning of Section 22(e)(3) and 409A(a)(2)(c)(i) of the Code. The determination of your Disability        shall be made by the Committee in its sole discretion.                            “Retirement” shall mean (i) the termination of the Grantee’s employment, other than for Cause,        with the Company and its Affiliates if, at the time of such termination of employment, the Grantee has        attained at least age sixty two (62) and completed at least five (5) years of service with the Company and       its Affiliates (including service with Dover Corporation and its affiliates prior to the Company’s Spin-      Off), and (ii) the Grantee complies with the non-competition restrictions set forth below.                 

 

    Page 3         5.2 Misconduct.  If prior to the issuance of shares of Common Stock under this Agreement, the Grantee has      (i) used for profit or disclosed to unauthorized persons, confidential information or trade secrets of the      Company or any of its Subsidiaries, (ii) breached any contract with, violated any policy of the Company or     any of its Subsidiaries (including, without limitation, the Company’s Insider Trading and Confidentiality     Policy and Anti-hedging and Anti-pledging Policy, as such policies may be modified from time to time, or     violated any fiduciary obligation to the Company or any of its Subsidiaries, or (iii) engaged in unlawful     trading in the securities of the Company or any of its Subsidiaries or of another company based on     information gained as a result of that Grantee’s employment with, or status as a director to, the Company or     any of its Subsidiaries (each of (i), (ii) and (iii) shall be considered “Cause” under the Plan), unless such      misconduct or violation is waived in writing by the Compensation Committee or the General Counsel of the      Company, the Award shall automatically terminate and the Grantee shall not be entitled to receive any shares      of Common Stock under Section 4 or otherwise under this Agreement. (Copies of the current version of the     Company’s Anti-hedging and Anti-pledging Policy are available on the Company’s third-party stock plan      administrator’s website.)   By accepting this Agreement, Grantee acknowledges his/her understanding that     nothing contained in this Agreement limits Grantee’s ability to report possible violations of law or regulation     to, or file a charge or complaint with, the Securities and Exchange Commission, the Equal Employment     Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health     Administration, the Department of Justice, the Congress, any Inspector General, or any other federal, state or     local governmental agency or commission (“Government Agencies”).   Grantee further understands that this      Agreement does not limit Grantee’s ability to communicate with any Government Agencies or otherwise      participate in any investigation or proceeding that may be conducted by any Government Agency, including      providing documents or other information, without notice to the Company. Nothing in this Agreement shall      limit Grantee’s ability under applicable United States federal law to (i) disclose in confidence trade secrets to      federal, state, and local government officials, or to an attorney, for the sole purpose of reporting or      investigating a suspected violation of law or (ii) disclose trade secrets in a document filed in a lawsuit or      other proceeding, but only if the filing is made under seal and protected from public disclosure.      6. Restrictions on Transfer. The Award and the shares of Common Stock issued under this Agreement may not      be sold, transferred or otherwise disposed of and may not be pledged or otherwise hypothecated until such      shares have vested and been issued.         7. Non-Competition. The enhanced benefits of Retirement provided to Grantee hereunder shall be subject to the      provisions set forth herein. If Grantee terminates due to Retirement, Grantee shall be deemed to have     expressly agreed not to engage, directly or indirectly in any capacity, in any business in which the Company     or any Affiliate at which Grantee was employed at any time in the three (3) years immediately prior to     termination of employment was engaged, as the case may be, in the geographic area in which the Company     or such Affiliate actively carried on business at the end of Grantee’s employment there, for the period     remaining after Grantee’s termination of employment until the end of the  Performance Period set forth     herein.  In the event that Grantee fails to comply with the non-compete provisions set forth herein, Grantee     shall forfeit the enhanced benefits realized upon a termination due to Retirement referred to above and shall     return to the Company the economic value theretofore realized by reason of such benefits, as determined by     the Committee. If the non-compete provisions of this Award shall be unenforceable, the Committee may     rescind the benefits of Retirement set forth above.            8. Limitation of Rights.  During the Performance Period, the Grantee shall not have any rights of a stockholder      (including voting rights) or the right to receive any dividends declared or other distributions paid with respect to      any PSUs or shares of Common Stock which may be issued pursuant to this Award.             9. Taxes. Prior to the delivery to the Grantee (or the Grantee’s estate, if applicable) of book entry shares with      respect to the PSUs in respect of which all restrictions have lapsed, the Grantee (or the Grantee’s estate) shall     pay to the Company the federal, state and local income taxes and other amounts as may be required by law to be     withheld by the Company (the “Withholding Taxes”) with respect to such shares of Common Stock.  By     accepting and returning this Agreement in the manner provided in Section 15, the Grantee (or the Grantee’s     estate) shall be deemed to elect to have the Company withhold whole shares of Common Stock having an     aggregate Fair Market Value equal to the Withholding Taxes in satisfaction of the Withholding Taxes, such     election to continue in effect unless or until the Grantee (or the Grantee’s estate): (i) notifies the Company not  

 

    Page 4         less than 10 days before such delivery that the Grantee (or the Grantee’s estate) will satisfy such obligation in      cash prior to delivery of the shares of Common Stock to the Grantee: and (ii) not less than 2 days prior to     delivery of the shares  of Common Stock pays the Withholding Taxes in cash to the Company or its designee, in     which event the Company shall not withhold a portion of such shares of Common Stock as otherwise provided     in this Section 8. Any fraction of a share which would be required to satisfy Withholding Taxes obligation shall     be disregarded and the remaining amount due shall be paid in cash by the Grantee.      10. IRS Section 409A. This Award is intended to comply with or be exempt from Section 409A of the Code to      the maximum extent possible.  If the Company determines that the Award granted under this Agreement is or      may be subject to Section 409A of the Code, then the shares of Common Stock that are scheduled to be      issued to the Grantee upon “separation from service” will be delayed until the first day of the seventh month      following your “separation from service” with the Company or its “affiliates” within the meaning of Section      409A (or following the date of participant’s death, if earlier) to the extent required to comply with Section      409A of the Code.    11. Clawback. Grantee acknowledges that this Award is subject to the Company’s Clawback Policy, as in effect      on the date of this Agreement. (A copy of the current version of the Company’s Clawback Policy is available      on the Company’s third-party stock plan administrator’s website.)   12. Grantee Bound by the Plan.  The Grantee hereby acknowledges receipt of a copy of the Plan and agrees to be      bound by all the terms and provisions thereof.  (A copy of the current version of the Plan is available on the     Company’s third party stock plan administrator’s website.)      13. Nontransferability. Neither this Agreement nor the Award is transferable by the Grantee except as provided      or permissible under the Plan.      14. Acceptance. The PSUs granted to the Grantee pursuant to the Award shall be subject to the Grantee’s      acceptance of this Agreement.  Grantee is required to accept this Award either: (a) electronically within     his/her stock plan account with the Company’s stock plan administrator according to the procedures then in     effect; or (b) by returning an executed counterpart of this Agreement to the Company.  The acceptance of     this Award constitutes acknowledgement of receipt of the Plan and consent to the terms of the Plan and this     Award as described in the Plan and this Agreement.      15. No Right to Continued Employment.  Nothing in this Agreement or the Plan shall interfere with or limit in      any way the right of the Company or its Subsidiaries to terminate the Grantee’s employment, nor confer      upon the Grantee any right to continuance of employment by the Company or any of its Subsidiaries or      continuance of service as a Board member.            16. Non-US Employees.  For Non-US Employees, and employees and employees who transfer employment      outside of the United States during the term of the PSU, the PSU award is subject to the conditions of the     attached Appendix B attached hereto for Non-US Employees.           17. Modification of Agreement.  The provisions of this Agreement may not be amended without the written      consent of Grantee where such amendment would materially impair Grantee’s rights under this Agreement.       No course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the      validity, binding effect or enforceability of this Agreement.  Notwithstanding the foregoing, the Committee      retains discretion, without the need to obtain the consent of the Grantee, to determine and adjust payouts in      accordance with Section 3 hereof and the Appendix A attached hereto.          18. Severability.  Should any provisions of this Agreement be held by a court of competent jurisdiction to be      unenforceable or invalid for any reason, the remaining provisions of this Agreement shall not be affected by      such holding and shall continue in full force in accordance with their terms.       19. Governing Law.  The validity, interpretation, construction and performance of this Agreement shall be      governed by the laws of the State of Delaware without giving effect to any conflicts of laws principles.      

 

Page 5   20. Successors in Interest.  This Agreement shall inure to the benefit of and be binding upon any successor to the    Company.  This Agreement shall inure to the benefit of the Grantee’s legal representatives.  All obligation    imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon    the Grantee’s heirs, executors, administrators and successors.  21. Resolution of Disputes. Any dispute or disagreement which may arise under, or as a result of, or in any way    relate to, the interpretation, construction or application of this Agreement shall be determined by the    Committee.  Any determination made hereunder shall be final, binding and conclusive on the Grantee, the    Grantee’s heirs, executors, administrators and successors, and the Company and its Subsidiaries for all    purposes.  22. Entire Agreement. This Agreement and the terms and conditions of the Plan constitute the entire    understanding between the Grantee and the Company and its Subsidiaries, and supersede all other    agreements, whether written or oral, with respect to the Award.  23. Headings.  The headings of this Agreement are inserted for convenience only and do not constitute a part of    this Agreement.  24. Counterparts.  This Agreement may be executed or accepted simultaneously in two or more counterparts,    each of which shall constitute an original, but all of which taken together shall constitute one and the same    agreement.  KNOWLES CORPORATION   By:   GRANTEE   __________________________________________________  SignatureExhibit 4.2

 

WARRANT
TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY 

SHARES

 

SAFE-T
GROUP LTD.

 

Warrant
No: _______

Number
of American Depositary Shares: _______

 

	 	Issue Date:
    _______, 2018

 

THIS
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that,
for value received, _____________, located at ___________________, or its assigns (the “Holder”) is entitled,
upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the
date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary
of the Initial Exercise Date (the “Termination Date”), provided that, if such date is not a Trading Day, the
Termination Date should be the immediate following Trading Day but not thereafter, to subscribe for and purchase from Safe-T Group
Ltd., a company organized under the laws of the State of Israel (the “Company”), up to ______ Ordinary Shares,
no par value (the “Ordinary Share(s)”) (as subject to adjustment hereunder, the “Warrant Shares”),
represented by _____ American Depositary Shares (“ADSs”), as subject to adjustment hereunder, and the ADSs
issuable upon exercise of this Warrant (the “Warrant ADSs”). The purchase price of one Warrant ADS shall be
equal to the Exercise Price, as defined in Section 2(b).

 

Section
1. Definitions. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:

 

“Accredited
Investor” has the meaning set forth in Rule 501 of Regulation D promulgated under the Securities Act.

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States, a
legal holiday in the State of Israel or any day on which banking institutions in the State of New York or in the State of Israel
are authorized or required by law or other governmental action to close.

 

“Deposit
Agreement” means the Deposit Agreement dated as of June 2, 2017, as amended, among the Company, The Bank of New York
Mellon as Depositary and the owners and holders of ADSs from time to time, as such agreement may be amended or supplemented.

 

“Depositary”
means The Bank of New York Mellon, as Depositary under the Deposit Agreement.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Ordinary
Share Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Ordinary Shares or ADSs, including, without limitation, any debt, preferred stock, right, option, warrant
or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder
thereof to receive, Ordinary Shares or ADSs.

  

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

     

     

    

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Subsidiary”
means each subsidiary of the Company (collectively, the “Subsidiaries”).

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the ADSs and/or the Ordinary Shares are listed or quoted
for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global
Select Market, the New York Stock Exchange, or the Tel Aviv Stock Exchange (or any successors to any of the foregoing).

 

Section
2. Exercise.

 

a) Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or
agency that the Company may designate by notice in writing to the registered Holder at the address of the Holder appearing on
the books of the Company) and the Depositary of a duly executed facsimile copy or PDF copy submitted by electronic mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier
of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant
ADSs specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank. No
ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant ADSs available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three
(3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant ADSs available hereunder shall have the effect of lowering
the outstanding number of Warrant ADSs purchasable hereunder in an amount equal to the applicable number of Warrant ADSs purchased.
The Holder and the Company shall maintain records showing the number of Warrant ADSs purchased and the date of such purchases.
The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. If there
is no effective registration statement under the Securities Act permitting the issuance of Warrant ADSs upon exercise of this
Warrant, a Holder may not exercise the purchase rights represented by this Warrant unless such Holder, at the time of such exercise,
is an Accredited Investor and such Holder, at the Company’s request, represents the same to the Company in writing. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
following the purchase of a portion of the Warrant ADSs hereunder, the number of Warrant ADSs available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.

 

Notwithstanding
the above, this Warrant may not be exercised on the Record Date (as such term is defined under the Tel-Aviv Stock Exchange Ltd.
(the “TASE”) rules and regulations) of: (i) a distribution of bonus shares; (ii) a rights offer; (iii) any
distribution of dividends; (iv) a consolidation of the share capital of the Company; (v) a share split; or (vi) a reduction of
the share capital of the Company (each of the aforementioned events shall be called: “Corporate Event”). In
addition, if the Ex-Date (as such term is defined under the TASE rules and regulations) of a Corporate Event occurs before the
Record Date of a Corporate Event, then the Warrant shall not be exercised on the Ex-Date.

 

Without
limiting the liquidated damages provision in Section 2(d)(i) and the buy-in provision in Section 2(d)(iv), in no event will the
Company be required to net cash settle a Warrant exercise.

 

    	 	2	 

     

    

 

b)
Exercise Price. The exercise price per ADS under this Warrant shall be $______, subject to adjustment hereunder
(the “Exercise Price”).

 

c)
[Reserved]

 

d) Mechanics
of Exercise.

 

i. Delivery
of Warrant ADSs Upon Exercise. The Company shall cause its registrar to deposit the Warrant Shares subject to such exercise
with the Israeli custodian of The Bank of New York Mellon, the Depositary for the ADSs (the “Depositary”),
and cause the Depositary to credit the account of the Holder’s or its designee’s balance account with The Depository
Trust Company (or another established clearing corporation performing similar functions) through its Deposit/Withdrawal At Custodian
system (“DWAC”) if the Depositary is then a participant in such system and either (A) there is an effective
registration statement permitting the issuance of the Warrant ADSs to or resale of the Warrant ADSs by the Holder or (B) the Warrant
ADSs are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by
physical delivery of a certificate, registered in the name of the Holder or its designee, for the number of Warrant ADSs to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise, by the date
that is the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period
after the delivery to the Company of the Notice of Exercise (such date, the “Warrant ADS Delivery Date”) provided
that the Warrant ADS Delivery Date shall not be deemed to have occurred until such time that the Company has received the aggregate
Exercise Price. Upon delivery of the Notice of Exercise together with payment to the Company of the aggregate Exercise Price,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant ADSs with respect to
which this Warrant has been exercised, irrespective of the date of delivery of the Warrant ADSs. If the Company fails for any
reason to deliver to the Holder the Warrant ADSs subject to a Notice of Exercise by the Warrant ADS Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant ADSs subject to such
exercise (based on the VWAP of the ADS on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20
per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant
ADS Delivery Date until such Warrant ADSs are delivered or Holder rescinds such exercise. The Company agrees to maintain a depositary
that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable, if applicable. As used
herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading
Days, on the Company’s primary Trading Market with respect to the ADS as in effect on the date of delivery of the Notice
of Exercise.

 

ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant ADSs, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant ADSs called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

    	 	3	 

     

    

 

iii. Rescission
Rights. If the Company fails to cause the Depositary to transmit to the Holder the Warrant ADSs pursuant to Section 2(d)(i)
by the Warrant ADS Delivery Date, then the Holder will have the right to rescind such exercise; provided, however,
that the Holder shall be required to return any Warrant ADSs or Ordinary Shares subject to any such rescinded exercise notice
concurrently with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant ADSs and the restoration
of Holder’s right to acquire such Warrant ADSs pursuant to this Warrant (including, issuance of a replacement warrant certificate
evidencing such restored right).

 

iv. Compensation
for Buy-In on Failure to Timely Deliver Warrant ADSs Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Depositary to deliver to the Holder the Warrant ADSs in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant ADS Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases,
ADSs to deliver in satisfaction of a sale by the Holder of the Warrant ADSs which the Holder anticipated receiving upon such exercise
(a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the ADSs so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant ADSs that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant ADSs for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of ADSs that would have been issued
had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases ADSs
having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of ADSs with an aggregate sale
price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall
be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the
Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver ADSs upon
exercise of the Warrant as required pursuant to the terms hereof.

 

v. No
Fractional Warrant Shares or Scrip. No fractional Warrant Shares or Warrant ADSs shall be issued upon the exercise of this
Warrant. As to any fraction of an ADS which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole ADS.

 

vi. Charges,
Taxes and Expenses. Issuance of Warrant ADSs shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant ADSs, all of which taxes and expenses shall be paid by the Company,
and such Warrant ADSs shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant ADSs are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all standard Depositary fees required for same-day processing of any Notice of Exercise and all standard
fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the ADSs, if any. The Company shall pay all standard fees and expenses of the Depositary in connection
with the issuance of the Warrant ADSs hereunder.

 

    	 	4	 

     

    

 

vii. Closing
of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of
this Warrant, pursuant to the terms hereof.

 

e) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and
any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution
Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes
of the foregoing sentence, the number of Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of Ordinary Shares held by the Holder and its Attribution Parties plus the number of Ordinary Shares
represented by ADSs issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of Ordinary Shares represented by ADSs which would be issuable upon (i) exercise of the remaining, nonexercised portion
of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Ordinary
Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes
of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules
and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder
that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify
or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall
be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding
Ordinary Shares as reflected in (A) the Company’s most recent Annual Report on Form 20-F, Report on Form 6-K or other public
filings filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Depositary setting forth the number of Ordinary Shares outstanding. Upon the written or oral
request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing or by electronic mail to the Holder
the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined after
giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding Ordinary Shares was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of Ordinary Shares outstanding immediately after giving effect to
the issuance of Ordinary Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or
decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation
in no event exceeds 9.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Ordinary
Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase
in the Beneficial Ownership Limitation will not be effective until the sixty first (61st) day after such notice is
delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to
properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this
Warrant.

 

    	 	5	 

     

    

 

Section
3. Certain Adjustments.

 

a) Share
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise
makes a distribution or distributions on its Ordinary Shares or ADSs or any other equity or equity equivalent securities payable
in Ordinary Shares or ADSs (which, for avoidance of doubt, shall not include any ADSs issued by the Company upon exercise of this
Warrant), as applicable, (ii) subdivides outstanding Ordinary Shares or ADSs into a larger number of shares or ADSs, as applicable,
(iii) combines (including by way of reverse share split) outstanding Ordinary Shares or ADSs into a smaller number of shares or
ADSs, as applicable, or (iv) issues by reclassification of Ordinary Shares, ADSs or any shares of share capital of the Company,
as applicable, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number
of Ordinary Shares or ADSs, as applicable (excluding treasury shares, if any), outstanding immediately before such event and of
which the denominator shall be the number of Ordinary Shares or ADSs, as applicable, outstanding immediately after such event,
and the number of Ordinary Shares or ADSs, as applicable, issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any
Subsidiary thereof, as applicable, sells or grants any option to purchase, or sell or grant any right to reprice, or otherwise
dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Ordinary Shares or
Ordinary Share Equivalents, at an effective price per share less than the Exercise Price then in effect.

 

b) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record
holders of any class of Ordinary Shares or ADSs (the “Purchase Rights”), then, if and only if an adjustment
pursuant to this subsection would cause the Exercise Price to be reduced, the Exercise Price shall be multiplied by a fraction,
of which the denominator shall be the price per share of the Ordinary Shares or ADSs, as applicable, on the closing of last Trading
Day prior to the Ex-Date set in connection with such offer, and of which the numerator shall be the price per share of the Ordinary
Shares or ADSs, as applicable, on the applicable Ex-Date set in connection with such offer.

 

c) Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of Ordinary Shares or ADSs, by way of return of
capital or otherwise (including, without limitation, any distribution of cash, shares or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a “Distribution”), at any time after the issuance of this Warrant, then, if and only if an adjustment pursuant
to this subsection would cause the Exercise Price to be reduced, in each such case, the Exercise Price shall be multiplied by
a fraction, of which the denominator shall be the price per share of the Ordinary Shares or ADS, as applicable, on the closing
of the last Trading Day prior to the Ex-Date of such distribution, and the numerator shall be the price per share of the Ordinary
Shares or ADSs, as applicable, on such Ex-Date.

 

    	 	6	 

     

    

 

d) Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Ordinary Shares (including any Ordinary Shares underlying
ADSs) are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the
holders of 50% or more of the outstanding Ordinary Shares (including any Ordinary Shares underlying ADSs), (iv) the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary
Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for
other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than
50% of the outstanding Ordinary Shares (including any Ordinary Shares underlying ADSs) (not including any ADSs and Ordinary Shares
held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party
to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Ordinary Share represented
by each Warrant ADS that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of
shares of capital stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any
additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction
by a holder of the number of Ordinary Shares represented by each Warrant ADS for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share or ADS, as applicable,
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Ordinary Shares
or ADSs are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this
Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the Ordinary Shares represented by each Warrant ADS acquirable and receivable upon exercise of this Warrant (without regard to
any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares
or ADSs pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon
the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from
and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring
to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company
and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect
as if such Successor Entity had been named as the Company herein.

 

    	 	7	 

     

    

 

e) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of an ADS, as the case may be.
For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be
the sum of the number of Ordinary Shares (including Ordinary Shares underlying ADSs, but excluding treasury shares, if any) issued
and outstanding.

 

f) Notice
to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting
adjustment to the number of Warrant ADSs and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Ordinary Shares or ADSs, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary
Shares or ADSs, (C) the Company shall authorize the granting to all holders of the Ordinary Shares or ADSs rights or warrants
to subscribe for or purchase any shares of share capital of any class or of any rights, (D) the approval of any shareholders of
the Company shall be required in connection with any reclassification of the Ordinary Shares or ADSs, any consolidation or merger
to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory
share exchange whereby the Ordinary Shares are converted into other securities, cash or property, or (E) the Company shall authorize
the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear
upon the Warrant Register of the Company, at least 5 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares or ADSs of record
to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such
reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Ordinary Shares of record shall be entitled to exchange their Ordinary Shares for
securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity
of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Report on Form 6-K. The Holder shall remain entitled to exercise this Warrant
during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.

 

Section
4. Transfer of Warrant.

 

a) Transferability.
Subject to compliance with any applicable securities laws and the conditions hereof, this Warrant and all rights hereunder are
transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the
Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company
within two (2) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant in full.
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant ADSs without
having a new Warrant issued.

 

b) New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original
Issue Date and shall be identical with this Warrant except as to the number of Warrant ADSs issuable pursuant thereto.

 

    	 	8	 

     

    

 

c) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

  

Section
5. Miscellaneous.

 

a) No
Rights as Shareholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
ADSs, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of
the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c) Fridays,
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d) Authorized
Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Ordinary
Shares a sufficient number of shares to provide for the issuance of the Warrant ADSs and underlying Ordinary Shares upon the exercise
of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of issuing the Warrant Shares needed for the Depositary to issue the necessary
Warrant ADSs upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as
may be necessary to assure that such Warrant Shares and Warrant ADSs may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the applicable Trading Market upon which the Ordinary Shares and ADSs
may be listed. The Company covenants that all Warrant ADSs which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant ADSs in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created
by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its articles of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant ADSs above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant ADSs upon the exercise
of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.

 

    	 	9	 

     

    

 

Before
taking any action which would result in an adjustment in the number of Warrant ADSs for which this Warrant is exercisable or in
the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

 

e) Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed
and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law
thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of
New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City
of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper
or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees
that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be
deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an
action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for their reasonable attorneys’ fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding.

 

f) Restrictions.
The Holder acknowledges that the Warrant ADSs acquired upon the exercise of this Warrant, if not registered, will have restrictions
upon resale imposed by state and federal securities laws.

 

g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that
all rights hereunder terminate on the Termination Date, if the Company willfully and knowingly fails to comply with any provision
of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall
be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those
of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of
its rights, powers or remedies hereunder.

 

h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
to the Holder at the address set forth in the Recitals hereto.

 

i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant ADSs, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Ordinary Shares or ADSs or as a shareholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

    	 	10	 

     

    

 

j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled
to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert
the defense in any action for specific performance that a remedy at law would be adequate.

 

k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure
to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant ADSs.

 

l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective
to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions
of this Warrant.

 

n) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of
this Warrant.

 

********************

 

(Signature
Page Follows)

 

  

    	 	11	 

     

    

  

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

	 	SAFE-T
    GROUP LTD.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	 	12	 

     

    

 

NOTICE
OF EXERCISE

 

To:
SAFE-T GROUP LTD.

 

(1)
The undersigned hereby elects to purchase ________ Warrant ADSs of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any, in lawful money of the United States.

  

(2) Please
register and issue said Warrant ADSs in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

(3)
The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933,
as amended.

 

The
Warrant ADSs shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity: ________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity: _________________________________________________

Name
of Authorized Signatory: ___________________________________________________________________

Title
of Authorized Signatory: ____________________________________________________________________

Date:
________________________________________________________________________________________

  

    	 	13	 

     

    

  

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase Warrant ADSs.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	______________________________________
	 	(Please Print)
	 	 
	Address:	______________________________________
	 

         

        Phone
        Number:

         

        Email
        Address:
	(Please
        Print)

         

        ______________________________________

         

        ______________________________________

	 	 
	Dated: _______________
    __, ______	 
	 	 
	Holder’s Signature:
    _______________________	 
	 	 
	Holder’s Address:
    ________________________	 

 

 

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]